In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

China is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China’s ...

Home-grown start-up Mirxes is going places, but co-founder is firmly rooted in Singapore. Read more at straitstimes.com. Read ...

While MIC2025 was officially shelved from public discourse in 2018 due to intense international backlash, its core objectives ...

On , Shanghai Moyom Biotechnology Co., Ltd. unveiled its breakthrough regenerative aesthetic innovation, Aphranel ...

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company” or "Zhengye”), a veterinary vaccine manufacturer that ...

Singapore biotech firm Mirxes began trading in Hong Kong on May 23 at a valuation exceeding US$1 billion. Read more at ...